How Does Jesse’s Journey Choose Who to Fund?
Our goal is to continue to grant at least $1M per year to fund research into Duchenne muscular dystrophy. To date, we have funded more than $11.5 million in research projects worldwide, dedicated to finding a cure for Duchenne muscular dystrophy.
But how does Jesse’s Journey choose which research projects to fund?
Annually, Jesse’s Journey invites researchers worldwide to submit Duchenne-related research applications for funding. Through recommendations from our Research Funding Advisory Committee (RFAC) to our Board of Directors, we make annual grants to research to the most promising research in the field of Duchenne muscular dystrophy. The RFAC is comprised of clinicians, scientists and DMD parents. The parents of children with Duchenne have a starkly different time reference: they are fighting for the lives of their sons, and to them, every day makes a difference. Their participation on the Committee continues to be a driving force in the selection of relevant and Duchenne-focused research proposals under consideration for funding. Moreover, they constitute an important and intimate link between research and those we are trying to save.
The RFAC is established to solicit and evaluate research initiatives and proposals to determine which project or combination of projects has the greatest potential to be translated into clinical treatment of Duchenne muscular dystrophy.
Applications for funding will be assessed based on defined criteria including:
- The research proposal’s fit with the mandate and goals of the Foundation
- The proposed research strategy and methodology
- The researcher’s qualifications and experience
- The proposed plan and/or timeline for translation to the clinic
- The proposed budget
- Accessibility of the proposed program to exchange with other investigators
Our granting cycle for applications begins in September of each year and project grants are awarded in June. For more information on making an application for research funding please contact Dr. Lisa Hoffman or Perry Esler.